Why IMU is a multi multi bagger, page-24284

Oooft… seems like they haven’t got much else’s to look at…Bisantrene hasn’t been in a patient for decades.

The two main studies it was in patients it performed worse than the SOC and then a Phase III which apparently did as good as SOC but I can’t seem to find the study data on that.

Since then, AML therapies are leaps ahead and even on the solid tumour front anthracyclines have gone a way to reduce cardio toxicity…So bisantrene would really need to knock it out of the park, and how long in the clinic will that take to prove against SOC and which patient population? Have they even got a trial in the works?!

FTO inhibition is the other angle but there are more selective compounds (FB23-2 & CS1) that have shown very strong FTO inhibition with less ‘off target’ effects. Given bisantrene seems to insert itself into the patients DNA there is no data on the long term adverse neural and immune outcomes. If there is potential negative effects would patients prefer a therapy that could alter their DNA or not?

Yep there’s a lot to be concerned about on the RAC side, perhaps why procrastinating on HC makes more sense.

Your comments made me think of the below…is There a correlation between posting/hallway monitoring on HC and share price?!